Conventional imaging methods have limited sensitivity for detecting metastatic prostate cancer. With appropriate, timely treatment vital to survival and quality of life, better imaging has been an ongoing goal.  A recent study, reported in the January issue of The Journal of Nuclear Medicine, has now shown in a prospective, systematic manner that a PET/CT scan, using the radiotracer F-18-DCFBC to target prostate-specific membrane antigen (PSMA), is significantly more effective than other detection methods currently in use. {read more here}